Gold nanoparticles loaded with FLT3 inhibitors had an increased transmembrane delivery in AML cells, and the in vitro evaluation indicates that the FLT3-IDT gene was downregulated, leading to tumor cell suppression (Petrushev et al., 2016). The gene discussed is FLT3; the disease is acute myeloid leukemia.